Unraveling the RSV vaccine clinical trial data

Mar 02, 2023

∙ Paid

Yesterday, VRBPAC— FDA’s external scientific committee—met to discuss the latest clinical trial data for RSV vaccines. This is a big deal because it could be the first RSV vaccine to market— something we’ve been waiting on for decades. (Literally since the 1960s, with the first RSV vaccine candidates ending in terrible failure among kids.)

The purpose of…

Continue reading this post for free, courtesy of Katelyn Jetelina.

Or purchase a paid subscription.

A guest post by

Edward Nirenberg

Views my own, but you can borrow them if you feel so inclined. Anti-disease. Big Nerd Energy. “A homework person.” Fun at parties. Antibody hoarder. “Problematically literate.”he/him